The objective was to compare the incidence of adverse reactions reported with three nonsteroidal anti-inflammatory drugs with different cyclo-oxygenase (COX)-2 selectivity. All spontaneous adverse reaction notifications in the pharmacovigilance database of the World Health Organisation Collaborating Centre for International Drug Monitoring with aceclofenac, meloxicam, and rofecoxib that were re...

MELOXICAM is a NSAID classified as a derivative of enolic acid, licensed to treat acute and chronic musculoskeletal disorders in the dog. Meloxicam achieves maximal plasma concentration 4.5 hours after oral administration, has a low volume of distribution (0.3 l/kg), is highly plasma protein bound (97 per cent) and has an elimination half-life of 24 hours in dogs (EMA 2011). Steady state pharma...

The purpose of the present study was to evaluate anti-nociceptive effects of morphine, tramadol, meloxicam and their combinations in rats. Seventy male Wistar rats were divided into seven equal groups and randomly assigned to receive intraperitoneal saline (S) (control group, 1.0 mL kg-1), morphine (MO) (4.0 mg kg-1), tramadol (TR) (12.5 mg kg-1), meloxicam (ML)...

NSAIDs (nonsteroidal anti-inflammatory drugs) are a class of drugs with analgesic, anti-inflammatory, and antipyretic effects. Diclofenac sodium is one of the world's most widely-prescribed NSAIDs. Meloxicam is another NSAID that was approved in the last several years. Treatment with NSAIDs may result in renal damage. Relatively, little is known about comparative nephrotoxicity of NSAIDs. There...

The incidence of upper gastrointestinal (GI) complications of non-steroidal anti-inflammatory drugs remains the most common side effect. The objective of this study was to compare the incidence of upper gastrointestinal complications of Ibuprofen as non-selective non-steroidal anti-inflammatory drug (NSAID) to Celecoxib and Meloxicam as selective non-steroidal antiinflammatory drugs. This study...

Meloxicam is a non steroidal anti-inflammatory drug, used in the treatment of rheumatoid arthritis and oestoarthritis. It is practically insoluble in water leading to poor dissolution, variations in bioavailability and gastric irritation on oral administration. In order to modulate its gastric side effect and to increase aqueous solubility, physical mixture and solid dispersion of the drug were...

for Vets in that what the authors were describing were not clinical guidelines, we wish to highlight that meloxicam is the only NSAID licensed for the relief of postoperative pain following dehorning in calves. This is based on extensive work looking at a variety of measures of assessing pain and wellbeing, including physiological and behavioural parameters. One example of these measures is use...

AIM to know the effect of piroxicam (COX-1 and COX-2 inhibitor NSAID) and meloxicam (selective COX-2 inhibitor NSAID) against the gastric mucosa. METHODS a random, double-blind-parallel study and repeat measurement against 20 elderly-patients with knee-OA was conducted. Patients were divided into 2 equal groups, every group got piroxicam 20 mg/day or meloxicam 15 mg/day for 3 weeks. On the se...

This study evaluated the action of ionizing radiation and the possible radioprotective effect of the non-steroidal anti-inflammatory drug meloxicam on the bone physiology of rat mandibles by assessing the alveolar socket healing and bone strength. Forty male Wistar rats were divided in 4 groups (n=10): control (CG), irradiated (IG), meloxicam (MG), meloxicam irradiated (MIG). A dose of 0.2 mg/k...

Vasopressin increases urine concentration through activation of aquaporin-2 (AQP2) in the collecting duct. Nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandin E2 synthesis, and may suppress AQP2 producing a urine concentrating defect. There are four serines in AQP2 that are phosphorylated by vasopressin. To determine if chronic use of NSAIDs changes AQP2's phosphorylation at any o...